The acute and long-term L-DOPA effects are independent from changes in the activity of dorsal raphe serotonergic neurons in 6-OHDA lesioned rats

Correspondence Cristina Miguelez, PhD, Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU) 48940 Leioa, Spain. E-mail: cristina.miguelez@ehu.es

Received 7 July 2015; Revised 15 January 2016; Accepted 21 January 2016

C Miguelez1,2, S Navailles3,4, P De Deurwaerdère3,4 and L Ugedo1

1Department of Pharmacology, Faculty of Medicine and Dentistry, University of the Basque Country (UPV/EHU), Leioa, Spain, 2Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz, Spain, 3Université de Bordeaux, Institut des Maladies Neuродегénératives, Bordeaux, France, and 4CNRS, Institut des Maladies Neuродегénératives, Bordeaux, France

BACKGROUND AND PURPOSE
L-DOPA is still the most efficacious pharmacological treatment for Parkinson’s disease. However, in the majority of patients receiving long-term therapy with L-DOPA, its efficacy is compromised by motor complications, notably L-DOPA-induced dyskinesia. Evidence suggests that the serotonergic system is involved in the therapeutic and the side effects of L-DOPA. Here, we investigate if long-term L-DOPA treatment alters the activity of the dorsal raphe nucleus (DRN) and its responses to serotonergic drugs.

EXPERIMENTAL APPROACH
We measured the responses of serotonergic neurons to acute and chronic L-DOPA treatment using \textit{in vivo} electrophysiological single unit-extracellular recordings in the 6-OHDA-lesion rat model of Parkinson’s disease.

KEY RESULTS
The results showed that neither acute nor chronic L-DOPA administration (6 mg·kg\(^{-1}\) s.c.) altered the properties of serotonergic-like neurons. Furthermore, no correlation was found between the activity of these neurons and the magnitude of L-DOPA-induced dyskinesia. In dyskinetic rats, the inhibitory response induced by the 5-HT\(_{1A}\) receptor agonist 8-OH-DPAT (0.0625–16 \(\mu\)g·kg\(^{-1}\), i.v.) was preserved. Nonetheless, L-DOPA impaired the ability of the serotonin reuptake inhibitor fluoxetine (0.125–8 mg·kg\(^{-1}\), i.v) to inhibit DRN neuron firing rate in dyskinetic animals.

CONCLUSIONS AND IMPLICATIONS
Although serotonergic neurons are involved in the dopaminergic effects of L-DOPA, we provide evidence that the effect of L-DOPA is not related to changes of the activity of DRN neurons. Rather, L-DOPA might reduce the efficacy of drugs that normally enhance the extracellular levels of serotonin.

LINKED ARTICLES
This article is part of a themed section on Updating Neuropathology and Neuropharmacology of Monoaminergic Systems. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.13/issuetoc

Abbreviations
8-OH-DPAT, 8-hydroxy-2-(dipropylamino)tetralin; AIM, abnormal involuntary movements; DRN, dorsal raphe nucleus; L-DOPA, L-3,4-dihydroxyphenylalanine; LID, L-DOPA-induced dyskinesia; 6-OHDA, 6-hydroxydopamine; PD, Parkinson’s disease; SSRI, selective serotonin reuptake inhibitor
Introduction

Parkinson’s disease (PD) is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta and subsequent striatal dopamine depletion. Pharmacological replacement with L-3,4-dihydroxyphenylalanine (L-DOPA) sets the basis of the standard treatment for PD. However, long-term administration of L-DOPA induces a range of abnormal involuntary movements (AIM) known as L-DOPA-induced dyskinesia (LID), which affects up to 40% of PD patients within 5 years of treatment (Manson et al., 2012). The mechanisms underlying LID are still not well understood, but evidence suggests that the serotonergic system plays a crucial role both in the therapeutic and side effects of L-DOPA (see Navailles et al. (2013)).

The dorsal raphe nucleus (DRN) contains the main population of serotonergic neurons in the brain and provides extensive innervation to the basal ganglia nuclei (Di Matteo et al., 2008). A growing amount of preclinical data indicates that serotonergic neurons mediate some of the behavioural effects of L-DOPA attributed to an enhancement of dopaminergic tone such as L-DOPA-induced rotating behaviour or LID (Hollister et al., 1979; Carta et al., 2007; Eskow et al., 2009). These findings agree with neurochemical data reporting that serotonergic neurons are involved in the release of the L-DOPA-derived dopamine in the brain (Tanaka et al., 1999; Navailles et al., 2010). Acute administration of 5-HT1A receptor agonists or selective serotonin reuptake inhibitors (SSRI) reduces the expression of LID (Carta et al., 2007; Dupre et al., 2007; Munoz et al., 2008; Bishop et al., 2012; Bezard et al., 2013; Fidalgo et al., 2015), dopamine release (Kannari et al., 2001; Yamato et al., 2001; Lindgren et al., 2010; Navailles et al., 2010) and neuronal activity in the DRN (Martin-Ruiz and Ugedo, 2001; Miguelez et al., 2011b). Additionally, pharmacological lesion of the DRN ameliorates LID (Carta et al., 2007; Eskow et al., 2009), while transplantation of serotonergic neuron grafts exacerbates them (Carlsson et al., 2007). The activity of serotonergic neurons thus appears to be a key component of the effects of L-DOPA.

The serotonergic system undergoes various changes as a consequence of dopamine depletion or to the chronic administration of L-DOPA (Miguelez et al., 2011b; Miguelez et al., 2014a). In case of LID, discriminative and anatomical changes in the serotonergic innervation or serotonergic receptors have been reported in the striatum of dyskinetic animals or patients (Zhang et al., 2007, 2008; Rylander et al., 2010; Riahi et al., 2011), but not in the DRN (Rylander et al., 2010; Bishop et al., 2012; Inden et al., 2012). Nevertheless, prolonged treatment with L-DOPA reduces the number of serotonergic cells in the DRN leading to a decrease in serotonin content (Stanley and Yamamoto, 2014) and basal serotonin release (Navailles et al., 2011) in various brain areas. In addition, chronic L-DOPA treatment lowered and strengthened the ability of L-DOPA to enhance dopamine release and inhibit serotonin release, respectively (Navailles et al., 2011; Nevalainen et al., 2011). Although acute L-DOPA does not alter the firing rate of serotonergic neurons (Miguelez et al., 2013), these findings would be compatible with an altered electrophysiological responsiveness of serotonergic neurons consequent to its chronic administration.

In the present study, we sought to clarify if the expression of LID is associated with changes of the responsiveness of serotonergic neurons to L-DOPA. We investigated, using extracellular single-cell recordings in vivo, the electrophysiological characteristics of serotonergic neurons in the DRN of 6-hydroxydopamine (6-OHDA) lesioned rats, rendered dyskinetic by prolonged L-DOPA administration. The electrophysiological properties of serotonergic neurons were further studied with the 5-HT1A receptor agonist 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) and the SSRI fluoxetine.

Methods

Animals

All animal care and experimental protocols conformed to the European Economic Community (86–6091 EEC) and Spanish Law (RD 1201/2005) for the care and use of laboratory animals, and were approved by the Local Ethical Committee for Animal Research at the University of the Basque Country (approved protocols: 17-P07-02/2009, 17-P07-05/2009 and 185/2011). Experiments involving animals are reported in accordance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015). All procedures were as humane as possible, and efforts were made to reduce the number of animals used. Experiments were performed with Sprague–Dawley rats (Harlan, Barcelona, Spain) weighing 220–225 g on arrival and housed under a 12:12 h light:dark cycle with food and water ad libitum. A total of 72 animals were used in this study.

Tables of Links

| Targets | Ligands |
|---------|---------|
| GPCRs<sup>5</sup> | 8-OH DPAT, 8-hydroxy-2-(dipropylamino)tetralin |
| SERT, SLC6A4 | Amphetamine |
| Transporters<sup>9</sup> | L-DOPA |
|  | Fluoxetine |

These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (<sup>1,2</sup>Alexander et al., 2015a,b).
**Experimental design and groups**

As illustrated in Figure 1A, at the beginning of the experiment, animals received 6-OHDA or its vehicle in the medial forebrain bundle. Two weeks after, all animals received d-amphetamine and were tested for rotational screening. Four weeks from the beginning of the experiment, animals were divided into four groups according to the type of lesion and chronic treatment received (saline or L-DOPA), and AIMS were evaluated for at least 3 weeks. Twenty-four hours after the last dose of L-DOPA or saline, electrophysiological experiments were performed in all animals, and after transcardial perfusion, brain tissue was processed for histological verifications. The groups included in this study are referred to as sham/saline (n = 18), sham/L-DOPA (n = 16), 6-OHDA/saline (n = 15) and 6-OHDA/L-DOPA (n = 23). Animals were assigned to groups following a randomized block design. Before the surgery, animals were labelled and assigned to either sham-lesioned or 6-OHDA-lesioned group using a table of random numbers to select the labelled animals. Then, animals within each group were randomly assigned to treatment conditions, saline or L-DOPA. The experimental procedure was unblinded due to the lack of experimenters involved.

**6-OHDA lesion and rotational screening**

The 6-OHDA lesion procedure was performed according to previous protocols (Miguelez et al., 2011a; Aristieta et al., 2012). To protect noradrenergic neurons, desipramine (25 mg·kg⁻¹, i.p.) was administered 30 min before the infusion of 6-OHDA. Then, rats were anaesthetized with isoflurane and mounted on a Kopf stereotaxic frame. Two injections of 2.5 and 2 μL of 6-OHDA (free-base, 3.5 μg μL⁻¹) were then given at two coordinates into the right medial forebrain bundle (relative to bregma, toothbar set at −2.4; AP: −4.4 mm; MD: +1.2 mm, DV: −7.8 mm; toothbar set at +3.4 mm; AP: −4. mm; MD: +0.8 mm, DV: −8 mm) at a rate of 1 μL min⁻¹. Sham animals were equally treated, but received the vehicle of 6-OHDA instead of the toxin.

Two weeks after 6-OHDA lesion, animals were given 2.5 mg·kg⁻¹ of d-amphetamine to screen for the severity of the dopaminergic loss. Ipsilateral rotations were recorded for 90 min. Only rats rotating more than five full turns per minute, corresponding to a >90% striatal dopamine depletion, were selected for receiving chronic treatment with saline or L-DOPA.

**Abnormal involuntary movement (AIM) rating**

The development of L-DOPA-induced AIM was monitored and scored according to a rat dyskinesia scale described previously (Miguelez et al., 2011a; Aristieta et al., 2012). AIM were induced by daily s.c. injections of L-DOPA (6 mg kg⁻¹ in combination with the peripheral decarboxylase inhibitor benserazide, 12 mg·kg⁻¹, s.c.) over 3 weeks. Afterwards, the dosage was changed to a maintenance dose (i.e. a twice-weekly administration regimen). On the testing days, rats were placed individually in transparent empty plastic cages prior to drug administration and observed for 1 min every 20 min for 3 h following L-DOPA injection. Three subtypes of dyskinetic movements (axial, limb and orolingual AIM) and asymmetric locomotive behaviour (cognitive AIM) were scored on a basic severity scale in which each item is rated on a scale from 0 to 4 depending on its duration. In addition, axial limb AIM were rated on an amplitude scale from 0 to 4. Axial, limb and orolingual AIM were analysed and expressed as follows: sum AIM, sum of axial, limb and orolingual AIM scores (basic severity scale) for an entire testing session; Global AIM: for each AIM subtype, the basic severity score was multiplied by the amplitude score on each monitoring period, and all of these scores were summed for each testing session. In this study, 20 out of 23 6-OHDA-lesioned animals developed stable dyskinesia, while three of them remained non-dyskinetic. Because no difference was found between dyskinetic and non-dyskinetic animals, both groups were pooled together. Sham animals and 6-OHDA-lesioned animals treated with saline did not develop dyskinetic movements.

**Figure 1**

Experimental design and histological verifications. (A) At the beginning of the study, animals were injected with 6-OHDA or saline into the right medial forebrain bundle. Two weeks later, the severity of the 6-OHDA lesion was checked by amphetamine-induced rotations. To develop stable AIM, rats were injected daily with 6 mg·kg⁻¹ L-DOPA (plus 12 mg·kg⁻¹ benserazide) or saline for 21 days, and AIM were rated 2–3 days per week. At the end of the chronic treatment, L-DOPA was administered twice per week, and electrophysiological experiments were performed. At the end of the study, all animals were transcardially perfused, and the brains were removed, sectioned and stored for subsequent histological procedures. (B) Histological verification of the recording site in the DRN (Bi), dopaminergic denervation in the striatum and substantia nigra compacta from a control (Bii) or 6-OHDA-lesioned rat (Biii). DRN, dorsal raphe nucleus; Aq, aqueduct. The number of animals included was 18, 16, 15 and 23 for sham/saline, sham/L-DOPA, 6-OHDA/saline, 6-OHDA/L-DOPA respectively. Scale bar 400 μm.
**Extracellular single unit recordings of dorsal raphe neurons**

Single-unit extracellular recordings of DRN neurons were performed as described previously (Miguelez et al., 2011b; 2013). Animals were anaesthetized with chloral hydrate (400-mg·kg\(^{-1}\), i.p.) and placed on a stereotaxic frame where the body temperature was maintained at ~37°C for the entire experiment. After ligature and division of the sagittal sinus, the recording electrode consisting of an Omegadot single-barrel glass micropipette (filled with a 2% solution of Pontamine Sky Blue in 0.5% sodium acetate) was lowered into the DRN (in millimetre relative to: AP: +1.0, ML: 0, DV: −4.5 to −6.0). Serotonergic neurons were identified by the following criteria: (1) wide-duration action potentials that occurred between 1 and 2 ms positive-negative spikes, (2) a regular rhythm and (3) a slow firing rate (0.5–3 Hz). Burst-firing DRN serotonergic neurons were identified as described in Hajos et al. (1995a), by criteria including fired-spike doublets or triplets with an intraburst time-interval <20 ms. Firing pattern, firing rate and the coefficient variation of pattern (ratio of SD to the mean interval value of an interspike time-interval histogram, as percent) were analysed offline using the computer software Spike2 (Cambridge, England). Only one cell was studied per animal when any drug was administered. At the end of each experiment, a Chicago Sky Blue 6B (Sigma-Aldrich, Spain) mark was deposited at the recording site by passing a 5 μA cathodic current for 10 min through the recording electrode (Figure 1B).

After electrophysiological recordings, animals were deeply anaesthetized and transcardially perfused with 4% ice-cold buffered paraformaldehyde prepared in 0.1 M phosphate buffer. Brains were removed and transferred to a 25% sucrose solution until they sank. The brains were cut in coronal 40 μm sections using a freezing microtome (HM 430, Microm, Germany). Slices containing the DRN were stained using Neutral Red (Miguelez et al., 2011b) to verify the recording site. All cells included in the study were confirmed to belong to the DRN. Slices containing the striatum were processed for tyrosine hydroxylase (TH) immunostaining to qualitatively confirm the alterations of dopaminergic fibres expected after induction of the 6-OHDA lesions.

**Pharmacological treatments**

Electrophysiological recordings were performed in sham and 6-OHDA-lesioned animals chronically treated with L-DOPA or saline (6-OHDA/L-DOPA, 6-OHDA/saline, sham/L-DOPA and sham/saline groups). To match behavioural experiments, L-DOPA was used at a dose of 6 mg·kg\(^{-1}\) (plus 12 mg·kg\(^{-1}\) of benserazide, s.c.). Basal DRN firing rate and coefficient of variation were measured every 20 for 60 min in the four groups (at least 180 s of stable discharge activity) 24 h after the last dose of L-DOPA or saline and after an acute L-DOPA challenge. Sixty minutes after L-DOPA challenge, increasing doses of fluoxetine (0.125–16 mg·kg\(^{-1}\), i.v.) were tested. After complete inactivation of serotonergic neuron activity, the S-HT\(_{1A}\) antagonist WAY 106035 (50 μg·kg\(^{-1}\), i.v.) was administered for recovery of cell firing. In another set of the four experimental groups, the inhibitory influence of the S-HT\(_{1A}\) agonist 8-OH-DPAT (0.0625–16 mg·kg\(^{-1}\), i.v.) was assessed on DRN neuron activity 24 h after the last L-DOPA or saline administration and subsequently blocked by WAY 106035 (50 μg·kg\(^{-1}\), i.v.).

**Immunohistochemistry for TH and dopaminergic loss verification**

After inactivation of endogenous peroxidases [3% H\(_2\)O\(_2\) and 10% methanol in potassium-PBS (KPBS) for 30 min], sections were pre-incubated for 1 h in 5% normal goat serum +0.25% Triton X-100 in KPBS. The sections were incubated for 36 h at 4°C with the primary antibody (rabbit anti-TH, Pel-Freez Biologics, P40101-O) diluted at 1:1000. Subsequently, the sections were treated with a biotinylated goat antibody against rabbit IgG (BA 1000, Vector Laboratories, Burlingame, CA, USA) diluted at 1:200 for 2 h. The primary and secondary antibodies were diluted respectively in 5% or 2.5% normal goat serum +0.5% Triton X-100. Thereafter, sections were incubated with an avidin–biotin–peroxidase complex (ABC kit, PK-6100, Vector Laboratories, 1 h). Finally, the peroxidase reaction was developed with 3,3’-diaminobenzidine and 0.03% H\(_2\)O\(_2\). Sections were rinsed, mounted onto gelatin-coated slides, dehydrated, cleared with xylene and coverslipped.

OD was measured in three sections containing the striatum. First, capture was performed using a digital camera, and mean OD was visualised using image analysis NIH-produced software, ImageJ (http://rsb.info.nih.gov/nih-image/default.html). The whole striatum was delineated, and its OD was expressed as a percentage of that on the contralateral intact side after background subtraction (background was measured in the cortex on the side ipsilateral to the lesion). All the animals included in the study had a severe dopaminergic loss and showed >90% reduction in TH-fibre density in the striatum on the side ipsilateral to the lesion.

**Statistical analysis of data**

The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015). Experimental data were analysed using the computer programme GraphPad Prism (v. 5.01, GraphPad Software, Inc, La Jolla, CA, USA). The data were expressed as the mean values ± SEM, and the level of probability that constitutes the threshold for statistical significance was P < 0.05. To analyse the basic electrophysiological characteristics, the effect of L-DOPA on DRN cell activity or firing reversion induced by WAY 106035, a two-way ANOVA was used. F values provided correspond to the factor interaction (lesion*treatment). When ANOVA was significant, Bonferroni post hoc test was subsequently used. The proportion of cell type was analysed by \( \chi^2 \). Linear regression analyses were used to assess correlations between electrophysiological and behavioural data by using Pearson’s test. DRN basal electrophysiological parameters were calculated as the average of four to seven neurons per animal monitored 24 h after the last injection of the chronic L-DOPA treatment. DRN electrophysiological parameters after acute L-DOPA challenge were taken from 1 neuron per animal monitored for 60 min after L-DOPA injection in 6-OHDA/L-DOPA rats. Data compiled from dose–response curves of fluoxetine or 8-OH-DPAT were analysed for the best simple nonlinear fit to the three-parameter logistic equation (Parker and Waud, 1971). The following equation was used:

\[
E = E_{\text{max}}[A]^n/(ED_{50}^n + [A]^n),
\]

where [A] is the dose of the drug, E is the effect on the firing rate induced by A, \( E_{\text{max}} \) is the maximal effect, \( ED_{50} \) is the effective
dose for eliciting 50% of the Emax and n is the slope factor of the dose–response curve. Extra sum-of-squares F-test was used for statistical comparison of ED50 values among groups. In the dose–response curves, normalized data was used to avoid distorted results due to the variation in firing among the different cells and to better evaluate the drug effect.

Materials
L-DOPA methyl ester hydrochloride, 6-OHDA hydrochloride, benserazide hydrochloride, desipramine hydrochloride, chloral hydrate, d-amphetamine sulphate, WAY 100635 maleate salt, (±)-8-OH-DPAT hydrobromide were purchased from Sigma (Sigma-Aldrich, St Louis, MO, USA) and (±)-fluoxetine hydrochloride was purchased from Tocris (Tocris Bioscience, UK). Chloral hydrate, desipramine, L-DOPA, benserazide, amphetamine, WAY-100635 and (±)-8-OH-DPAT were prepared in 0.9% saline, (±)-fluoxetine in distilled water and 6-OHDA in deionized water containing 0.2 mg·mL−1 ascorbate. Except for chloral hydrate, drugs were prepared on the day of the experiment.

Results
Basal DRN neuronal activity and correlation with dyskinetic behaviour
Chronic L-DOPA administration (6 mg·kg−1 plus benserazide 12 mg·kg−1 for 21 days) led to a rapid onset of AIM in the majority of the 6-OHDA-lesioned rats. As detailed previously (Miguelez et al., 2011a; Aristieta et al., 2012), animals developed axial, limb, orolingual and locomotive AIM that increased during the first week of treatment and reached a plateau by the second week. All 6-OHDA-lesioned animals included in the study showed a marked loss of TH-positive fibre density in the ipsilateral striatum, corresponding to the ipsilateral side turning behaviour recorded after amphetamine (data not shown, Figure 1B).

A total of 596 serotonergic neurons were recorded in the DRN: 160 neurons from the sham/saline group (n = 18 animals), 122 neurons from the sham/L-DOPA group (n = 16), 133 neurons from the 6-OHDA/saline group (n = 15) and 181 neurons from the 6-OHDA/L-DOPA group (n = 23). DRN neurons were recorded 24 h after the last saline or L-DOPA injection. The basal firing rate and coefficient of variation were determined for single spiking and bursting cells (Table 1). In the first set of experiments, only single-spiking cells were recorded, but in the last group of experiments, both types of cells were registered and analysed. Single-spiking cells from both sets were pooled together because no differences were observed. In those experiments where both types of cells were recorded, the percentage of bursting cells was as follows: sham/saline, 46 ± 2%; sham/L-DOPA, 34 ± 3%; 6-OHDA/saline, 42 ± 4%; and 6-OHDA/L-DOPA, 41 ± 6% (obtained from 7, 9, 10 and 11 animals, respectively). The respective proportion of each cell type did not vary among the four groups (χ2 = 3.14, df = 3, n.s.). No difference was observed in the basal firing rate of single spiking (F(1,432) = 0.54, n.s.) and bursting cells (F(1,163) = 0.01, n.s.) in the DRN. Similarly, no differences were detected as for the coefficient of variation of DRN cells (F(1,404) = 3.10, n.s. for single-spiking cells and F(1,162) = 0.47, n.s. for bursting cells). In the bursting cells, mean spikes per burst was always two, regardless of the experimental group. These results confirmed that firing frequency and pattern remained unchanged among the groups.

No correlation was found between either the basal firing rate or pattern of DRN neurons and the AIM score in the 6-OHDA/L-DOPA group (statistical values are detailed in Table 2) (Figure 2E).

Effect of L-DOPA challenge on DRN neuronal activity and correlation with dyskinetic behaviour
In the 6-OHDA/L-DOPA group, AIM expression reached a peak 60 min after the administration of L-DOPA (Figure 2A). Therefore, the reactivity of DRN serotonergic neurons to a subsequent challenge of L-DOPA was investigated every 20 min for 1 h after the acute administration of L-DOPA (6 plus 12 mg·kg−1 benserazide, s.c.) (Figure 2B).

Acute L-DOPA did not alter the firing frequency or pattern of any of the studied groups measured 60 min after the administration (F(1,29) = 0.03 for frequency and F(1,29) = 0.02 for pattern, n.s. for both) (Figure 2C–D). Although exogenous L-DOPA is transformed in dopamine into serotonergic neurons, L-DOPA failed to alter firing properties in any of the neurons.

Table 1
Basal electrophysiological properties of DRN neurons in control and 6-OHDA-lesioned rats that received chronic saline or L-DOPA treatment

| Cell type       | Parameter            | Sham/saline | Sham/L-DOPA | 6-OHDA/saline | 6-OHDA/L-DOPA |
|-----------------|----------------------|-------------|-------------|---------------|---------------|
| Single spiking  | Basal firing rate (Hz)| 1.65 ± 0.07 | 1.76 ± 0.09 | 1.49 ± 0.09   | 1.50 ± 0.07   |
|                 | Coefficient of variation (%) | 28.90 ± 0.92 | 29.07 ± 0.97 | 29.35 ± 1.04 | 26.19 ± 0.94 |
| Bursting       | Basal firing rate (Hz)| 1.43 ± 0.11 | 1.41 ± 0.13 | 1.47 ± 0.11   | 1.46 ± 0.12   |
|                 | Coefficient of variation (%) | 83.74 ± 7.77 | 86.67 ± 15.62 | 83.57 ± 5.60 | 105.2 ± 11.11 |
|                 | % bursting cells      | 46 ± 2      | 34 ± 3      | 42 ± 4        | 41 ± 6        |

Rats were treated daily with saline or L-DOPA (6 mg·kg−1 in combination with benserazide 12 mg·kg−1, s.c.) for at least 21 days. All neurons were recorded 24 h after the last administration of saline or L-DOPA. Each value represents the mean ± SEM basal firing rate or coefficient of variation. Each cell was recorded for 180 s. The number of single-spiking and bursting cells analysed were, respectively, 109 and 51 in sham/saline, 92 and 30 in sham/L-dopa, 99 and 34 in 6-OHDA/saline, 129 and 51 in 6-OHDA/L-DOPA. The number of animals included was 18, 16, 15 and 23 for sham/saline, sham/L-DOPA, 6-OHDA/saline, 6-OHDA/L-DOPA respectively.

5-HT neurons and L-DOPA-induced dyskinesia

British Journal of Pharmacology (2016) 173 2135–2146 2139
groups for the following 60 min after the administration. For instance, the basal firing rate of DRN neurons before or 60 min after L-DOPA administration varied from 1.24 ± 0.07 to 1.32 ± 0.99 Hz in the 6-OHDA/saline group (n = 9) and from 1.56 ± 0.6 to 1.51 ± 0.03 Hz in the 6-OHDA/L-DOPA group (n = 11).

Additionally, no correlation was found between the DRN firing rate or pattern and AIM scores calculated 60 min after L-DOPA administration for the 6-OHDA/L-DOPA group (statistical values are detailed in Table 2) (Figure 2F).

**Influence of fluoxetine and 8-OH-DPAT on DRN neuronal activity**

The sensitivity of serotonergic neurons to the inhibitory effect of fluoxetine on DRN firing properties involves an increase in the extracellular levels of serotonin that, subsequently, stimulates 5-HT1A receptors. The inhibitory effect of fluoxetine should be affected if acute and/or chronic L-DOPA modifies the extracellular levels of serotonin.

The effect of fluoxetine was tested on DRN cells 60 min after an acute challenge of L-DOPA (6 mg·kg⁻¹). In agreement with previous work from our laboratory (Miguelez et al., 2011b; Miguelez et al., 2013), cumulative doses of fluoxetine (0.125–8 mg·kg⁻¹, i.v.) dose-dependently decreased DRN firing rate in all studied groups (Figure 3A–B). The dose–response curve of fluoxetine was shifted to the right in rats chronically treated with L-DOPA, so that the mean ED50 value in this group was significantly higher than that obtained in sham/saline, sham/L-DOPA or 6-OHDA/saline (ED50: 0.75 ± 0.16 mg·kg⁻¹, n = 5 for sham/saline; ED50: 0.63 ± 0.14 mg·kg⁻¹, n = 6 for sham/L-DOPA; ED50: 0.51 ± 0.09 mg·kg⁻¹, n = 5 for 6-OHDA/saline; ED50: 1.67 ± 0.64 mg·kg⁻¹ n = 7 for 6-OHDA/L-DOPA, respectively, P < 0.05) (Figure 3C). This indicates that in the 6-OHDA/L-DOPA group, higher doses of fluoxetine were required to obtain the same inhibitory effect compared with the other groups. This inhibitory effect was reversed by a final injection of the 5-HT1A antagonist, WAY 100635 (50 μg·kg⁻¹, i.v.) (sham/saline: 91 ± 21%, n = 4; sham/L-DOPA: 124 ± 21%, n = 5; 6-OHDA/saline: 138 ± 48%, n = 4; 6-OHDA/L-DOPA: 43 ± 10%, n = 5). Reversal was complete in all but the 6-OHDA/L-DOPA group (F(1,14) = 5.79, P < 0.05; Figure 3D).

To ascertain if the rightward shift in the dose–response curve of fluoxetine in 6-OHDA/L-DOPA was dependent on changes in 5-HT1A autoreceptors, we tested the effect of the 5-HT1A receptor agonist 8-OH-DPAT 24 h after the last injection of L-DOPA or saline. As described for naïve animals (Martin-Ruiz et al., 2001), cumulative doses of 8-OH-DPAT (0.0625–16 μg·kg⁻¹, i.v.) induced a dose-dependent inhibition of DRN neuronal activity in all groups. Unlike fluoxetine, the inhibitory effect of 8-OH-DPAT was similar in all groups (ED50: 1.06 ± 0.12 mg·kg⁻¹, n = 9, for sham/saline; ED50: 1.02 ± 0.11 mg·kg⁻¹, n = 9, for sham/L-DOPA; ED50: 1.03 ± 0.57 mg·kg⁻¹, n = 8, for 6-OHDA/saline; ED50: 1.81 ± 0.79 mg·kg⁻¹, n = 11, for 6-OHDA/L-DOPA, n.s.) (Figure 4A). At the end of the experiment, the injection of WAY 100635 (50 μg·kg⁻¹, i.v.) totally reversed the basal firing frequency in all groups (F(1,23) = 0.08, n.s.; Figure 4B).

**Discussion**

Despite the central role of serotonergic neurons in the behavioural or biochemical responses to L-DOPA, our results

**Table 2**

Summary of Pearson’s r values for correlation between the severity of dyskinetic movements and the electrophysiological properties of DRN neurons in dyskinetic animals before and after L-DOPA administration.

| Abnormal involuntary movements | Basal | Firing rate 60 min after L-DOPA | Coefficient of variation |
|-------------------------------|-------|---------------------------------|------------------------|
| Sum AIM score                 |       |                                 |                        |
| Ax + Li + Or                  | r = 0.19 | r = –0.09             | r = 0.03               | r = 0.25               |
| Axial                         | r = 0.32 | r = 0.02                | r = 0.03               | r = 0.31               |
| Limb                          | r = 0.26 | r = 0.14                | r = 0.08               | r = 0.39               |
| Orolingual                    | r = –0.15 | r = –0.36           | r = –0.01             | r = 0.07               |
| Global AIM score              |       |                                 |                        |
| Ax + Li + Or                  | r = 0.07 | r = –0.27            | r = –0.15             | r = 0.05               |
| Axial                         | r = 0.32 | r = –0.08           | r = –0.14             | r = 0.17               |
| Limb                          | r = 0.25 | r = –0.09            | r = –0.01             | r = 0.23               |
| Orolingual                    | r = –0.38 | r = –0.53        | r = –0.14             | r = –0.15              |
| Locomotive AIM                | r = 0.23 | r = 0.24             | r = 0.18              | r = 0.20               |
indicate that these responses occur independently of changes in their electrical responsiveness to L-DOPA. The loss of efficacy of fluoxetine but preservation of 5-HT1A autoreceptors would suggest a better efficacy of 5-HT1A agonists in the treatment of L-DOPA-induced dyskinesia.

We observed that basal electrophysiological characteristics of DRN cells were identical in the four groups studied 24 h after the last L-DOPA administration, regardless the type of lesion or treatment followed. The effects of the selective loss of dopaminergic neurons on DRN cell activity has been a confounding factor, and different studies have revealed discrepant results with increased basal firing frequency (Zhang et al., 2007; Kaya et al., 2008; Wang et al., 2009; Prinz et al., 2013), decreased (Guiard et al., 2008) or no change (Miguelez et al., 2011b). Here, we found that the dopaminergic lesion did not alter the activity of serotonergic neurons, in agreement with the lack of changes observed on basal serotonin release in various brain areas (Navailles et al., 2010; Navailles and De

Figure 2
AIM expression and DRN responses to L-DOPA administration: correlation analysis. (A) Time course of global AIM scores (axial + limbic + orolingual) induced by L-DOPA on the last testing session of the chronic L-DOPA treatment (6 mg·kg⁻¹ plus benserazide 12 mg·kg⁻¹ for 21 days) in 6-OHDA rats (6-OHDA/L-DOPA group, n = 23). (B) Representative examples of DRN neuron firing frequency monitored for 60 min after L-DOPA administration in a 6-OHDA/saline rat and a 6-OHDA/L-DOPA rat. (C) Average basal firing rate monitored every 10 min for an hour after L-DOPA administration in the sham/saline (n = 7), sham/L-DOPA (n = 7), 6-OHDA/saline (n = 9) and 6-OHDA/L-DOPA (n = 11) groups. (D) Same as C for the coefficient of variation. (E) Regression analysis between Global AIM (AxLiOr) scores monitored on the last testing session of the chronic L-DOPA treatment, and basal electrophysiological parameters of DRN cells monitored 24 h after the last L-DOPA administration in 6-OHDA/L-DOPA rats (n = 10). (F) Regression analysis between Global AIM (AxLiOr) scores and electrophysiological parameters of DRN cells monitored on the 60th minute after L-DOPA administration in 6-OHDA/L-DOPA rats (n = 10). DRN basal electrophysiological parameters were calculated as the average of 4–7 neurons per animal monitored 24 h after the last injection of the chronic L-DOPA treatment. DRN electrophysiological parameters after acute L-DOPA challenge were taken from one neuron per animal monitored for 60 min after L-DOPA injection in 6-OHDA/L-DOPA rats. AIM, abnormal involuntary movements; Ax, axial; Li, limb; Or, orolingual.
**Figure 3**

Effect of fluoxetine on DRN serotonergic neurons after L-DOPA administration. (A–B) The histograms summarise the inhibitory effect of fluoxetine (0.125–16 mg·kg⁻¹, i.v.) on the firing rate of serotonergic neurons in the DRN from 6-OHDA saline (A) and 6-OHDA L-DOPA groups (B) 60 min after L-DOPA (6 mg·kg⁻¹ plus benserazide 12 mg·kg⁻¹, s.c.) administration. (C) Dose-effect curves illustrating the effect of fluoxetine on DRN cells in all studied groups. (D) Percentage of reversal from the basal firing rate produced by WAY 100635 (50 µg·kg⁻¹, i.v.) after complete inhibition induced by fluoxetine. \( N = 5, 6, 5 \) and 7 for sham/saline, sham/L-DOPA, 6-OHDA/saline, 6-OHDA/L-DOPA respectively. * \( P < 0.05 \) versus 6-OHDA/saline, Bonferroni post hoc test.

**Figure 4**

Effect of the 5-HT₁A receptor agonist, 8-OH-DPAT, on DRN serotonergic neuron activity. (A) Dose-effect curves depicting the inhibitory effect of cumulative doses of the 5-HT₁A agonist, 8-OH-DPAT (0.0625–16 µg·kg⁻¹, i.v.), on DRN cell firing in sham/saline, sham/L-DOPA, 6-OHDA/saline and 6-OHDA/L-DOPA groups. (B) Subsequent administration of the 5-HT₁A antagonist, WAY 100635 (50 µg·kg⁻¹, i.v.), totally restored the initial firing rate values. \( N = 9, 9, 8 \) and 11 for sham/saline, sham/L-DOPA, 6-OHDA/saline and 6-OHDA/L-DOPA groups respectively.
Deurwaerdere, 2012) and previous results from our laboratory (Miguelez et al., 2011b). Regarding chronic treatment with L-DOPA, our data are in line with studies reporting that the number of serotonergic neurons (Rylander et al., 2010; Inden et al., 2012), the tissue levels of serotonin or dopamine in the DRN (Bishop et al., 2012) or the serotonergic cell firing frequency (Prinz et al., 2013) remain unchanged in dyskinetic animals.

The most striking result of our study is the complete lack of changes evoked by L-DOPA on the electrical activity of serotonergic-like neurons during the 60 min following drug injection in any of the analysed groups. Furthermore, the linear regression analysis to correlate the severity of dyskinesia triggered by L-DOPA with the electrophysiological features of serotonergic-like neurons failed to show any significant correlation. One explanation for these latter results is that the use of anaesthetics may blunt the activity of DRN cells, which can vary according to the sleep–wake or motor state of the animal. The use of chloral hydrate as the anaesthetic in our experiments is relevant because this anaesthetic does not alter the basal firing rate of DRN neurons (McCardle and Gartside, 2012). Moreover, the use of anaesthetics until now has been necessary to study potential changes of electrophysiological responsivity of serotonergic neurons to pharmacological challenges (Hajos et al., 1995b; Guiard et al., 2008; Miguelez et al., 2011b; Miguelez et al., 2013). It allows one to address the reactivity of these cells and their electrophysiological properties using full cumulative dose–responses in vivo. These results are unexpected because they show that the inhibition of serotonin release following L-DOPA (Navailles et al., 2010), magnified after a chronic L-DOPA treatment (Navailles et al., 2011), was not related to changes of DRN serotonergic neuron activity.

In the last years, SSRIs have been assessed as possible antidyskinetic agents. Here, we tested the effect of fluoxetine on the activity of DRN neurons, 60 min after L-DOPA administration. We report that the dose–response and inhibitory curve induced by fluoxetine on the electrical activity of DRN neurons, not modified in 6-OHDA-lesioned or control animals (Miguelez et al., 2011b; Miguelez et al., 2013), was shifted to the right in dyskinetic animals. This result emphasizes a weaker effect of fluoxetine after chronic L-DOPA treatment and raises questions about the efficacy of SSRIs for treating L-DOPA-induced dyskinesia or depression associated with PD, because in those pathological situations, both drugs are chronically co-administered. Indeed, the efficacy of inhibitors of the serotonin transporter (SERT) relies on the extracellular levels of serotonin that indirectly stimulate somatic 5-HT1A receptors. In this regard, modifications of 5-HT1A autoreceptors in the DRN and basal ganglia in the different stages of Parkinsonism have been inconsistently reported. Parkinsonian patients on chronic L-DOPA treatment show decreased 5-HT1A receptor binding in the raphe (Doder et al., 2003), but fail to show major changes in several nuclei of the basal ganglia (Huot et al., 2012). In L-DOPA-primed MPTP-lesioned macaques, both an increased expression and no modification have been found, among others, in the caudate nucleus (Huot et al., 2012; Riahi et al., 2012). In Parkinsonian rats treated with saline or L-DOPA, reduced expression of 5-HT1A receptors has been reported in the striatum and prefrontal cortex (Mo et al., 2010; Zhang et al., 2014) together with a weaker inhibitory effect of 5-HT1A receptor agonists on DRN neurons and cortical interneurons from Parkinsonian animals (Wang et al., 2009; Zhang et al., 2014). Because the inhibitory effect of SSRIs in the DRN has been attributed, in part, to the activation of 5-HT1A receptors on cortical neurons (Hajos et al., 1999), one could explain the weaker effect of fluoxetine as a consequence of the loss of cortical control on the serotonergic neurons. However, in our hands, fluoxetine produced the same inhibitory effect in 6-OHDA and sham animals, confirming that the dopaminergic lesion does not modify the electrical response to the drug administration. In view of our results, the dyskinetic state was not related to an altered control exerted by 5-HT1A receptor agonists upon the electrical activity of DRN serotonergic-like neurons. Indeed, dose–effect curves performed under systemic administration of 8-OH-DPAT in control, Parkinsonian and dyskinetic animals revealed that the 5-HT1A receptor agonist equally inhibited the firing frequency of DRN neurons.

The changes proposed by other authors are, therefore, unlikely to interfere in our model. The loss of efficacy of fluoxetine in dyskinetic animals unrelated to altered 5-HT1A receptors could also not be related to changes of SERT expression. Indeed, in contrast to the divergent results regarding the striatal expression of the SERT in humans or rats (Calon et al., 2003; Kish et al., 2008; Politis et al., 2010; Rylander et al., 2010; Nevalainen et al., 2011; Prinz et al., 2013), the data concerning SERT expression in the DRN show unaltered levels in dyskinetic animals or humans (Chinaglia et al., 1993; Rylander, 2012). Considering that the SERT in the DRN is mainly involved in the inhibitory response to fluoxetine, these results discount the possibility that altered expression of SERT contributed to the weaker efficacy of fluoxetine in L-DOPA-treated dyskinetic animals. We cannot rule out the possibility that the changes reported in dyskinetic animals regarding the expression of 5-HT2C or 5-HT2A receptors (Zhang et al., 2007), known to bind fluoxetine (Palvimaki et al., 1996; Koch et al., 2002), contributed to the weaker effect of fluoxetine in dyskinetic animals. Nonetheless, the lower efficacy of fluoxetine parallels recent findings showing that high doses of the SSR1 citalopram are needed to obtain a reduction of LID, presumably by indirectly activating 5-HT1A autoreceptors (Fidalgo et al., 2015). Rather, the loss of inhibitory responses to fluoxetine or other SSRIs could highlight the loss of endogenous serotonergic tone after chronic treatment with L-DOPA (Navailles et al., 2011).

Our results are important in the context of the therapeutic use of SSRIs in the treatment of depression and dyskinesia in patients treated with L-DOPA. Regarding depression, it has been reported that L-DOPA worsens the antidepressant-like profile of fluoxetine in rats and that SSRIs display a weak efficacy in humans (Aarsland et al., 2009; Skapinakis et al., 2010; Miguelez et al., 2013). The efficacy of these compounds relies on their inhibitory action on DRN neuron firing rate, and considering also that moderate loss of serotonergic innervation has been reported in Parkinsonian patients (Kish et al., 2008), our data offer a good explanation for the lower efficacy of SSRIs against depression in patients treated with L-DOPA. The antidepressive profile is much more complicated to predict, because it involves the concomitant dopaminergic tone stimulated by L-DOPA from serotonergic terminals. The inhibition of serotonergic neurons by the stimulation of 5-HT1A autoreceptors, would reduce L-DOPA-stimulated dopamine release from serotonergic terminals (Tanaka et al., 1999; Navailles et al., 2010), thereby limiting the occurrence of dyskinesia. Our finding that the 5-HT1A receptor-dependent control of serotonergic neurons is still fully operational in dyskinetic animals agrees with the efficacy of 5-
HT_{1A} agonists in reducing both dopamine release and dyskinesia (Kannari et al., 2001; Carta et al., 2007; Iderberg et al., 2015b), particularly when targeting 5-HT_{1A} autoreceptors (Iderberg et al., 2015a). The SSRIs would be less efficacious than 5-HT_{1A} receptor agonists against dyskinesia due to their loss of efficacy to modulate serotonergic neurons. Clinical data show that the antidyskinetic effects of 5-HT_{1A} receptor agonism would be more robust compared with those of SSRIs (Mazzucchi et al., 2014; Svenningsson et al., 2015). Indeed, fluoxetine has been proposed to alleviate (Kuan et al., 2008; Bishop et al., 2012) or not (Dekundy et al., 2007) dyskinesia while a recent clinical data report a modest effect with SSRI (Mazzucchi et al., 2014). The extent to which SSRIs reduce LID via the decrease in the impulse-dependent/flow-dependent release of dopamine is unclear. Alternatively, one may consider the non-vesicular and SERT-dependent dopamine release triggered by L-DOPA (Miguelez et al., 2014b). This phenomenon occurs at doses comparable with those used in our study particularly in the hippocampus, and it might be a general phenomenon at higher doses of L-DOPA (Navailles et al., 2010). After long-term treatment with L-DOPA, it is possible that the proportion of the non-vesicular release of dopamine through the SERT increases with respect to the vesicular release. Additional data are warranted to further explore this possibility.

In this work, we conclude that the biochemical and behavioural effects of L-DOPA are independent from changes of electrical serotonergic neurons responsiveness. This implies that the changes of dopamine and serotonin release represent biochemical events at serotonergic axon terminals and dendrites. Nevertheless, the 5-HT_{1A} receptor-dependent control of serotonergic neurons is unaltered in dyskinetic rats, confirming that its stimulation may convey a decrease in the impulse-dependent release of L-DOPA-stimulated dopamine release and ultimately LID. The finding that fluoxetine loses its efficacy cautious the use of SSRI in the treatment of depression or dyskinesia in L-DOPA-treated Parkinsonian patients.

Acknowledgements

The project was funded by FIS PI 12/00613 and the University of the Basque Country (UFI 11/32 and IT 747-13), European Regional Development Fund (FEDER) and by the Fondation de France. We would like to thank UPV/EHU SGiker for their collaboration. P.D.D. acknowledges the support given by the cooperation for science and technology (COST) action CM1103.

Author contributions

C.M. performed the research, L.U. and C.M. designed the research study; C.M. analysed the data; C.M., L.U., S.N. and P.D.D. wrote the paper. All authors approved the final version of the manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organizations engaged with supporting research.

References

Aarsland D, Marsh L, Schrag A (2009). Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord 24: 2175–2186.

Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G Protein-Coupled Receptors. Br J Pharmacol 172: 5744–5869.

Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Facenda E, et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.

Aristieta A, Azkona G, Sagarduy A, Miguelez C, Ruiz-Ortega JA, Sanchez-Pernaute R, et al. (2012). The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PLoS One 7: e42652.

Brezard E, Munoz A, Tronci E, Pioli EY, Li Q, Porras G, et al. (2013). Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesias. Neurosci Res 77: 242–246.

Bishop C, George JA, Buchta W, Goldenberg AA, Mohamed M, Dickson SO, et al. (2012). Serotonin transporter inhibition attenuates L-DOPA-induced dyskinesia without compromising L-DOPA efficacy in heme-parkinsonian rats. Eur J Neurosci 36: 2839–2848.

Calon F, Morissette M, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003). Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov Disord 18: 241–253.

Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D (2007). Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease. J Neurosci 27: 8011–8022.

Carta M, Carlsson T, Kirik D, Bjorklund A (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesias in parkinsonian rats. Brain 130 (Pt 7): 1819–1833.

Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM (1993). Serotonergic terminal transporters are differentially affected in Parkinson’s disease and progressive supranuclear palsy: an autoradiographic study with [3 H]citalopram. Neuroscience 54: 691–699.

Curtis MJ, Bond RA, Spina D, Aaluwalla A, Alexander SP, Giembycz MA, et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.

Dekundy A, Lundblad M, Danysz W, Cenci MA (2007). Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179: 76–89.

Di Matteo V, Pierucci M, Esposito E, Crescimanno G, Benigno A, Di Giovanni G (2008). Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson’s disease and other motor disorders. Prog Brain Res 172: 423–463.
Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003). Tremor in Parkinson’s disease and serotoninergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60: 601–605.

Dupre KB, Eskow KL, Negron G, Bishop C (2007). The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158: 135–143.

Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C (2009). The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63: 610–620.

Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, et al. (2015). Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease. Neuroscience 298: 389–396.

Guiard BP, El Mansari M, Merali Z, Blier P (2008). Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11: 625–639.

Hajos M, Gartside SE, Sharp T (1995a). Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn Schmiedebergs Arch Pharmacol 351: 624–629.

Hajos M, Gartside SE, Villa AE, Sharp T (1995b). Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurones in the dorsal and median raphe nuclei of the rat. Neuroscience 69: 189–197.

Hajos M, Hajes-Korcso E, Sharp T (1999). Role of the medial prefrontal cortex in S-HT1A receptor-induced inhibition of S-HT neuronal activity in the rat. Br J Pharmacol 126: 1741–1750.

Holister AS, Breese GR, Mueller RA (1979). Role of monoamine neurons: an electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11: 625–639.

Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttmann M, et al. (2008). Preferential loss of serotonin markers in caudate versus putamen in Parkinson’s disease. Brain 131 (Pt 1): 120–131.

Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002). R-fluxoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27: 949–959.

Kuan WL, Zhao JW, Barker RA (2008). The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) 197: 279–293.

Lindgren HS, Andersson DR, Lagerkvist S, Nisbrandt H, Cenci MA (2010). L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112: 1465–1476.

Manson A, Stirpe P, Schrag A (2012). Levodopa-induced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis 2: 189–198.

Martin-Ruiz R, Ugedo L (2001). Electrophysiological evidence for postsynaptic 5-HT(1 A) receptor control of dorsal raphe 5-HT neurones. Neuropsychopharmacology 41: 72–78.

Mazzucchi S, Frosini D, Ripoli A, Nicoletti V, Linsalata G, Bonuccelli U, et al. (2014). Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson’s disease. Acta Neurol Scand 131: 1191–1195.

McCardle CE, Gartside SE (2012). Effects of general anaesthetics on 5-HT neuronal activity in the dorsal raphe nucleus. Neuropsychopharmacology 62: 1787–1796.

McCardle JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.

Miguelez C, Aristieta A, Cenci MA, Ugedo L (2011a). The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in Parkinsonian rats: an electrophysiological and behavioural study. PLoS One 6: e24679.

Miguelez C, Grandoso L, Ugedo L (2011b). Locus coeruleus and dorsal raphe neuron activity and response to acute antidepressant administration in a rat model of Parkinson’s disease. Int J Neuropsychopharmacol 14: 187–200.

Miguelez C, Berrocoso E, Mico JA, Ugedo L (2013). L-DOPA modifies the antidepressant-like effects of reboxetine and fluoxetine in rats. Neuropsychopharmacology 67: 349–358.

Miguelez C, Morera-Herreras T, Torrecilla M, Ruiz-Ortega JA, Ugedo L (2014a). Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson’s disease. Front Neural Circ 8: 21.

Miguelez C, Navailles S, Delaville C, Marquis L, Lagiere M, Benazzouz A, et al. (2014b). L-DOPA alters dopamine and serotonin release independently from electrophysiological changes in the dorsal raphe nucleus in vivo: Relevance to dyskinesia. In: Society for Neuroscience: Washington, DC.

Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X (2010). L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson’s disease. Neurobiol Aging 31: 926–936.

Munoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, et al. (2008). Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131 (Pt 12): 3380–3394.

Navailles S, Bioulac B, Gross C, De Deurwaerde P (2011). Chronic L-DOPA therapy alters central serotoninergic function and L-DOPA-
induced dopamine release in a region-dependent manner in a rat model of Parkinson’s disease. Neurobiol Dis 41: 585–590.

Navailles S, Boulauc B, Gross C, De Deurwaerdere P (2010). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson’s disease. Neurobiol Dis 38: 136–143.

Navailles S, De Deurwaerdere P (2012). Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson’s disease. Mol Neurobiol 45: 173–185.

Navailles S, Lagiere M, Contini A, De Deurwaerdere P (2013). Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem Neurosci 4: 680–692.

Nevalainen N, Af Bjerken S, Lundblad M, Gerhardt GA, Stromberg I (2011). Dopamine release from serotonergic nerve terminals and their ligands. Nucl Acids Res 42 (Database Issue): 6–1106.

Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SPH, et al. (2016). Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists. J Pharmacol Exp Ther 351: 440–447.

Prinz A, Selesnew LM, Liss B, Boeroer J, Carlsson T (2013). Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson’s disease. Exp Neurol 248C: 236–245.

Riahi G, Morissette M, Levesseque D, Rouillard C, Samadi P, Parent M, et al. (2012). Effect of chronic L-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain. Neurochem Int 61: 1160–1171.

Riahi G, Morissette M, Parent M, Di Paolo T (2011). Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinasias. Eur J Neurosci 33: 1823–1831.

Rylander D (2012). The serotonin system: a potential target for antidyskinetic treatments and biomarker discovery. Parkinsonism Relat Disord 18(Suppl 1): S126–S128.

Rylander D, Parent M, O’Sullivan SS, Dovero S, Lees AJ, Bezd E, et al. (2010). Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 68: 619–628.

Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V (2010). Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 10: 49.

Stansley BJ, Yamamoto BK (2014). Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus. J Pharmacol Exp Ther 351: 440–447.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Victorin K, Keywood C, Shankar B, et al. (2015). Eltoprazine counteracts L-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138(Pt 4): 963–973.

Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsuura M (1999). Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10: 631–634.

Wang S, Zhang QJ, Liu J, Wu ZH, Wang T, Gui ZH, et al. (2009). Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1 A) receptor stimulation in the rat. Neuroscience 159: 850–861.

Yamato H, Kannari K, Shen H, Suda T, Matsuura M (2001). Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum. Neuroreport 12: 1123–1126.

Zhang Q, Wang S, Zhang L, Zhang H, Qiao H, Niu X, et al. (2014). Decreased response of interneurons in the medial prefrontal cortex to 5-HT(1A) receptor activation in the rat 6-hydroxydopamine Parkinson model. Neurol Sci 35: 1181–1187.

Zhang X, Andren PE, Greengard P, Svenningsson P (2008). Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U SA 105: 2163–2168.

Zhang X, Andren PE, Svenningsson P (2007). Changes on 5-HT2 receptor mRNAs in striatum and subthalamic nucleus in Parkinson’s disease model. Physiol Behav 92: 29–33.